Testing a New Medication for Bronchiectasis Without Cystic Fibrosis

Plain-English translation of NCT06559150 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a medication called ensifentrine to see if it can help people with bronchiectasis—a condition where parts of the lungs are permanently damaged and scarred, causing chronic cough and frequent lung infections. Participants will either receive ensifentrine or a placebo (inactive treatment) alongside their usual care, and the study will track whether the medication reduces flare-ups, eases symptoms, and improves daily life over 6 to 12 months.

Currently, there are limited treatment options specifically designed to reduce lung infections and improve outcomes in people with this type of bronchiectasis. This medication may help by reducing airway inflammation and clearing mucus more effectively, potentially preventing serious infection flare-ups.

Do you qualify?

You likely qualify if…

you have been diagnosed with bronchiectasis (confirmed by a chest CT scan) that is not related to cystic fibrosis
you cough up mucus regularly and have had at least one lung infection requiring antibiotics in the past year
you are able to use a nebulizer (a breathing machine that delivers medication as a mist) correctly
you are willing to use contraception if you are male, pregnant, or breastfeeding, or able to become pregnant
you can perform breathing tests (spirometry) as instructed by study staff

You likely don't qualify if…

you have been diagnosed with COPD or asthma as your primary lung condition
you are a current smoker or a former heavy smoker with significant lung damage
you have primary ciliary dyskinesia, primary immunodeficiency, or are being treated for certain fungal or bacterial lung infections
your bronchiectasis is caused by cystic fibrosis or requires intravenous immunoglobulin treatment

What participation looks like

You will be randomly assigned to receive either ensifentrine or placebo through a nebulizer—a device you breathe in medication from—and neither you nor the study staff will know which one you're getting. You'll visit the clinic regularly over 6 to 12 months for breathing tests, sputum samples, and check-ins about your symptoms and quality of life. The study will track how often you have lung infection flare-ups and whether the medication helps you feel better and have fewer infections.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(51 sites)

United States

Kirklin Clinic of UAB Hospital, Birmingham, Alabama

So Cal Institute for Respiratory Diseases, Inc., Los Angeles, California

University of California Davis Medical Center, Sacramento, California

National Jewish Health Main Campus, Denver, Colorado

MedStar Georgetown University Hospital, Washington D.C., District of Columbia